Clinical Trial

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an investigator-initiated trial aimed at assessing the safety of anti-CD19 CAR-T cells in the treatment of refractory systemic lupus erythematosus.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-01-15; most recent amendment 2026-01-30.
Status change: Recruiting → Active, Not Recruiting 2025-08-26
Trial Details
NCT Number NCT06222853
Lead Sponsor The Children's Hospital of Zhejiang University School of Medicine
Collaborators: Chongqing Precision Biotech Co., Ltd
Conditions Systemic Lupus Erythematosus, CAR-T Cell Therapy
Enrollment 22 participants
Start Date 2024-02-10
Primary Completion 2025-04-04 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-04